Compare PEBO & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEBO | NBTX |
|---|---|---|
| Founded | 1902 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2005 | 2018 |
| Metric | PEBO | NBTX |
|---|---|---|
| Price | $35.17 | $35.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $37.33 | $36.00 |
| AVG Volume (30 Days) | ★ 137.7K | 60.4K |
| Earning Date | 04-21-2026 | 03-31-2026 |
| Dividend Yield | ★ 4.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $197,000.00 | N/A |
| Revenue This Year | $17.29 | $58.17 |
| Revenue Next Year | $2.97 | N/A |
| P/E Ratio | $43.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $27.49 | $4.29 |
| 52 Week High | $35.46 | $57.14 |
| Indicator | PEBO | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.56 | 40.76 |
| Support Level | $33.56 | $29.64 |
| Resistance Level | $35.46 | $41.89 |
| Average True Range (ATR) | 0.59 | 2.40 |
| MACD | 0.06 | -1.45 |
| Stochastic Oscillator | 91.77 | 2.24 |
Peoples Bancorp Inc (Marietta OH) is a financial holding company. As a community bank, it offers a complete line of banking, insurance, investment, and trust solutions through its financial subsidiaries. It offers demand deposit accounts, savings accounts, real estate mortgage loans, merchant credit card transaction processing services, corporate and personal trust services, life, health, property, and casualty insurance products, and brokerage services. The bank also offers telephone and internet-based banking through both personal computers and mobile devices.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.